Clinical Trial: CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07523009) titled 'CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA' on March 27.

Brief Summary: This study aimed to explore the efficacy and safety of cyclosporine (CsA) combined with eltrombopag (EPAG)/hetrombopag (HPAG) and romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe aplastic anemia (SAA)

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Severe Aplastic Anemia (SAA) Transfusion-dependent Non-severe Aplastic Anemia

Intervention: DRUG: Cyclosporine (CsA)

CsA 3-5mg/kg/d

DRUG: Thrombopoietin Receptor Agonist

Eltrombopag: initial d...